FDA OKs generic HIV prevention shot, widening access for lower-income countries
3 November 2026 · filed under 8a83754d30be
The U.S. Food and Drug Administration has approved a generic version of lenacapavir, the long-acting injectable used for HIV prevention, STAT News reported November 2. The filing came from Dr. Reddy’s Laboratories, according to the outlet’s account.
The approval marks a step toward broader access to the prevention shot in lower-income countries, where cost has limited distribution of the branded formulation. STAT News characterized the decision as a key move in widening that access across dozens of nations.
Lenacapavir, administered on an infrequent injectable schedule, has been positioned by public health officials as a tool for reducing new HIV infections, particularly in regions where adherence to daily oral prevention regimens has proven difficult. A generic version, once manufactured and distributed at scale, would lower per-dose costs compared to the original branded product, though the STAT News report did not specify pricing figures or a distribution timeline for the generic formulation.
The FDA’s clearance applies to the U.S. regulatory pathway; manufacturing and distribution to the lower-income countries referenced in the report would proceed through separate regulatory and procurement channels not detailed in the available account.
No further specifics on rollout dates, production capacity, or the full list of affected countries were included in the STAT News report as summarized.